Wednesday, March 6, 2013

Will Mylan's acquisition of Agila benefit Accel Partners?

›
Okay, the story goes like this.... Way back in 2007, Accel partners committed to invest & invested over the next three years 1....
1 comment:
Tuesday, March 5, 2013

What could VCs learn from the recent pharma deals involving biotechs with very early-assets?

›
My response on the blog post " Preclinical Biotech Structured Deals: Reflections on 2013′s Solid Start"   by Bruce Booth - post...
Saturday, March 2, 2013

What when the boundaries blur between VC & PE?

›
My response on the highly thought provoking blog post "Venture Capital 2.0"  by Drug Baron (David Grainger) - posted on 01/Mar/2...
1 comment:
Wednesday, February 27, 2013

Dialog on Drug Baron's post "The Primacy of Statistics: In defense of the pivotal Phase 3 Clinical Trial"

›
The Primacy of Statistics: In defense of the pivotal Phase 3 Clinical Trial By Drug Baron (David Grainger) http://www.tcpinnovation...
Wednesday, February 20, 2013

Has the rise of an Indian sun in drug discovery horizon turned out a no-show? OR is it a mere eclipse?

›
Looking up on google to put together my next post, I typed out the text “ Drug discovery prospects India” and the top most hit was that of...
2 comments:
Sunday, February 10, 2013

USER TRUST, the dope that can't be ignored in the race to monetizing cyber-social engagement – A commentary in light of the recent revamps to LinkedIn user experience

›
Okay, here goes… FEW STATS & STATEMENTS.. With a market cap of over US$16 billion & revenues forecast slated at US$1.4 b...
2 comments:
Sunday, February 3, 2013

Pfizer Venture Investments (PVI) - a quick analysis of portfolio companies, categories

›
Trying to understand the driving factors behind the trends of life science investments in 2012, I was wondering if VC & CVCs behave dif...
1 comment: